UAMS and Mayo Clinic researchers advance PROTAC technology for targeted molecular therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers at the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute and the Mayo Clinic have discovered a way to supercharge molecular cancer treatments to destroy more cancer-causing proteins in cells.

The research findings of UAMS’ Hong-yu Li, the Helen Adams and Arkansas Research Alliance Endowed Chair in Drug Discovery and professor of medicinal chemistry and chemical biology in the UAMS College of Pharmacy, and Haojie Huang, the Gordon H. and Violet Partels professor of cellular biology at the Mayo Clinic, were published in Advanced Science

Li and Huang’s research gives drug makers a new tool for enhancing molecular cancer treatment therapy with Proteolysis Targeting Chimeras technology. PROTACs are genetically engineered molecular compounds that bridge cancer-causing proteins with the molecules that seek to destroy them. 

The team found that adding an “oglio,” or oligonucleotide, to the PROTAC molecular compound helped degrade the targeted proteins completely, improving on conventional PROTACs. 

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login